Health Care

King Pharmaceuticals May Climb as Battered Drug Firms Lure Private Equity King Pharmaceuticals Inc., LifePoint Hospitals Inc. and Endo Pharmaceuticals Holdings Inc. may be buyout targets as private-equity firms seek companies battered by the economy and poised to gain from the U.S. health overhaul.

Glaxo Pulls Swine Flu Vaccine Batch in Canada to Probe Allergic Reaction Canadian doctors should hold off on using a batch of GlaxoSmithKline Plc’s swine flu vaccine while the company probes reports of higher-than-expected occurrences of a side effect known as anaphylaxis, a spokeswoman for the U.K. drugmaker said today.

European Flu Deaths Double Almost Every Two Weeks; Toll Below Seasonal Flu Swine flu deaths have doubled almost every two weeks since mid October in Europe, with 169 occurring in the past week, the European Center for Disease Control and Prevention said.

Merck Wins Dismissal of Second Fosamax Trial Over Claims of `Jaw Death' Merck & Co. won dismissal of the second case scheduled for trial over claims its osteoporosis drug Fosamax caused so-called jaw death.

Boehringer's Pradaxa Matches Warfarin as Clot Therapy in Head-to-Head Test Boehringer Ingelheim GmbH’s blood- thinning pill Pradaxa was as effective and safe as the standard therapy for potentially deadly clots, according to the results of a head-to-head study.

Democrats Show Signs of Disunity on Health Care as Debate Looms in Senate Democrats who united last week to bring a sweeping health-care plan to the U.S. Senate floor still need to settle disagreements in their own ranks to pass President Barack Obama’s top domestic initiative.

British Government Warns of Climate Change Dangers in New Poster Campaign The British government will today begin a poster campaign warning of the dangers of climate change, showing how the seasons could soon look different as a result of global warming.

Stada Shares Cut to `Neutral' at UBS; Rally May Limit Potential for Gains Stada Arzneimittel AG had its share rating lowered to “neutral” from “buy” at UBS AG, which said there is limited potential for additional price increases after a two-month rally.